"The trial will assess the combination of Lixte’s first-in-class protein phosphatase inhibitor LB-100 with a standard regimen for untreated, extensive stage-disease small cell lung cancer (ED-SCLC)..." Open PDF to view the entire press release.

Medical - Pharma - Biotech - Medical Devices - Healthcare - Telemedicine - Healthcare Technology - Healthcare IT
Your Source For Worldwide Business and Financial Opportunities
MedNews on financings, strategic relationships, products, services and technology, including launches
MedTalks videos featuring conversations with management of companies with business or financial objectives